Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
With
National Cancer Institute (NCI)
A qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
Age
18–45
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Are Hispanic, Latina, Black, or identify as socio-economically disadvantaged (any racial/ethnic background) as measured by an item of financial distress answering that they are "having difficulty paying the bills no matter what they do" to a question about their current household financial situation.18, 19
report a history of Stage 1-3 breast cancer
reports HR+ breast cancer and confirm that they have had a discussion with their doctor about adjuvant ET; OR indicate that they are taking ET, even if they do not know their HR status, answer they are HR-, or do not recall having a discussion about ET)
not in active treatment (e.g., chemotherapy, radiation), with the exception of Herceptin
at least 3 months, but no more than 3 years out of completion of active treatment
no evidence of recurrent/metastatic disease
at least 18, but\< 45 years of age at diagnosis of first invasive breast cancer
English or Spanish speaking
are willing to consent to the interview
You may not be if
HR- breast cancer and indicate they are not taking ET
HR+ breast cancer but do not confirm discussion of ET or indicate they are taking ET
Stage 0 (DCIS) breast cancer
Recurrent or metastatic disease
Less than 3 months or more than 3 years post-active treatment
Less than 18 years old or ≥45 years old at diagnosis
